DocGo Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DocGo Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $322.20M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $616.56M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $624.29M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $440.52M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $318.72M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $94.09M | Mar 15, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($182.40M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $19.99M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $6.86M | Mar 16, 2026 |
| FY2022 | Dec 31, 2022 | $34.58M | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $23.74M | Mar 14, 2023 |
| FY2020 | Dec 31, 2020 | ($4.22M) | Nov 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($178.03M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $28.69M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $15.05M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $21.83M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $15.36M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | ($168.8K) | Nov 24, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.56M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $11.59M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $10.86M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $5.38M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $3.32M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $1.19M | Mar 15, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.45M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $70.12M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($64.49M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $28.87M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($1.95M) | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | ($247.9K) | Nov 24, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.54M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $3.61M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $7.31M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $3.20M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $4.81M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $4.36M | Mar 15, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $217.10M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $455.62M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $490.45M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $393.28M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $309.60M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $100.17M | Mar 15, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.23M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $140.44M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $185.28M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $114.35M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $82.55M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $33.23M | Mar 15, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $144.01M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $320.92M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $300.79M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $273.23M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $219.58M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $55.00M | Mar 15, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 16, 2026 |
| FY2025 | Dec 30, 2025 | $19.00M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $47.43M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $47.54M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $38.90M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $8.69M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $6.61M | Mar 15, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($183.80M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($1.40M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($21.39M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($28.97M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($63.56M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($87.30M) | Mar 15, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.02M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $89.24M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $59.29M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $157.34M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $175.54M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $32.42M | Mar 15, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $235.6K | Mar 16, 2026 |
| FY2024 | Dec 31, 2024 | $17.7K | Feb 27, 2025 |
| FY2023 | Dec 31, 2023 | $69.7K | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $142.7K | Mar 15, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | 0 | Mar 15, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | 0 | Mar 15, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 98.64M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 101.91M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 104.06M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 102.41M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 100.13M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 76.49M | Mar 15, 2022 |